Pharmacoepidemiology in the Postmarketing Assessment of the Safety and Efficacy of Drugs in Older Adults
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Much of the information on safety and efficacy of drugs in older people is obtained after marketing. Pharmacoepidemiologic studies play an increasing role in obtaining this information. Pharmacoepidemiologic studies contribute significantly to knowledge of risks associated with medicines in older people and less so to that of benefits. Recent improvements in methodology in both pharmacoepidemiology and geriatric medicine have improved the validity and reduced the bias of these studies. Pharmacoepidemiologic studies are a critical component of assessing the risks of medicines in older people. Where possible, findings of pharmacoepidemiologic studies should be tested with well-conducted interventional randomized trials in relevant populations of older people.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyd, C. M., Darer, J., Boult, C., Fried, L. P., Boult, L., & Wu, A. W. (2005) · JAMA · doi:10.1001/jama.294.6.716 · Cited by 2,581 · cited 1×
“The current evidence base from randomized trials and disease-based clinical guidelines do not provide adequate guidance for these patients (25).”
BackgroundFick, D. M., Cooper, J. W., Wade, W. E., Waller, J. L., Maclean, J. R., & Beers, M. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.22.2716 · Cited by 2,389 · cited 1×
“Many risk assessment tools consider individual drugs or doses, such as the modified Beers’ criteria (83) or the Screening Tool of Older Person’s Prescriptions criteria (84).”
BackgroundVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“They can also define those people likely to respond to treatment, for example, Apo E allele status is associated with outcomes of treatment with acetylcholinesterase inhibitors in patients with mild cognitive impairment (71).”
BackgroundRates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720 · cited 1×
“0 mM with an HMG co-A reductase inhibitor is associated with a greater reduction in ischemic heart disease in younger than in older patients (46).”
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 1×
“This reaction was detected through data analysis by regulatory bodies (8,9) and confirmed by meta-analyses of randomized controlled trials (10) and observational pharmacoepidemiologic studies (11,12).”
MethodTrajectories of disability in the last year of life
Gill, T. M., Gahbauer, E. A., Han, L., & Allore, H. G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909087 · Cited by 894
Impact of Anticholinergics on the Aging Brain: A Review and Practical Application
Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008) · Aging Health · doi:10.2217/1745509x.4.3.311 · Cited by 862
Antipsychotic Drug Use and Mortality in Older Adults with Dementia
Gill, S. S., Bronskill, S. E., Normand, S.-L. T., Anderson, G. M., Sykora, K., Lam, K., Bell, C. M., Lee, P. E., Fischer, H. D., Herrmann, N., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-11-200706050-00006 · Cited by 624
Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Cited by
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15767 · Cited by 3,163
Gnjidic, D., Hilmer, S. N., Blyth, F. M., Naganathan, V., Waite, L., Seibel, M. J., McLachlan, A. J., Cumming, R. G., Handelsman, D. J., & Le Couteur, D. G. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.02.018 · Cited by 1,176
Self-citationO'Neil, C. K., Hanlon, J. T., & Marcum, Z. A. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.09.004 · Cited by 261
Hwang, Y. J., Dixon, S. N., Reiss, J. P., Wald, R., Parikh, C. R., Gandhi, S., Shariff, S. Z., Pannu, N., Nash, D. M., Rehman, F., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2796 · Cited by 136
Kersten, H., Molden, E., Tolo, I. K., Skovlund, E., Engedal, K., & Wyller, T. B. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls176 · Cited by 131
Metadata
- Authors
- Hilmer, S. N., Gnjidic, D., & Abernethy, D. R.
- Venue
- The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-08
- Volume
- 67A
- Issue
- 2
- Pages
- 181-188
- ISSN
- 1079-5006 (ISSN-L)
- 1758-535X
- OpenAlex
- W2118277994
- Cited by
- 60
- References
- 16
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacoepidemiology in the Postmarketing Assessment of the Safety and Efficacy of Drugs in Older Adults. https://app.cochat.ai/papers/10.1093/gerona/glr066
- The paper
- Hilmer, S. N., Gnjidic, D., & Abernethy, D. R. (2012). Pharmacoepidemiology in the Postmarketing Assessment of the Safety and Efficacy of Drugs in Older Adults. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. https://doi.org/10.1093/gerona/glr066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.